Shares of WuXi AppTec (WUXI APPTEC) plummeted by 5.36% on Monday, as the company announced that it is assessing options for its cell and gene therapy manufacturing business, WuXi Advanced Therapies (WuXi ATU).
In a statement, WuXi AppTec said it has not entered into any binding deals regarding the operations of WuXi ATU and acknowledged uncertainty as to whether it will eventually decide to dispose of the business or explore other options to retain and continue its operations.
The announcement has raised concerns among investors about the future prospects and potential restructuring or divestment of the WuXi ATU business, which specializes in cell and gene therapy manufacturing. Analysts have expressed mixed views on the impact of this move on WuXi AppTec's overall operations and profitability.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。